KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gilead Sciences (GILD) EBT (2016 - 2026)

Gilead Sciences filings provide 17 years of EBT readings, the most recent being $2.1 billion for Q4 2025.

  • On a quarterly basis, EBT fell 4.11% to $2.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $9.8 billion, a 1319.86% increase, with the full-year FY2025 number at $9.8 billion, up 1319.71% from a year prior.
  • EBT hit $2.1 billion in Q4 2025 for Gilead Sciences, down from $3.6 billion in the prior quarter.
  • In the past five years, EBT ranged from a high of $3.6 billion in Q3 2025 to a low of -$4.5 billion in Q1 2024.
  • Median EBT over the past 5 years was $1.9 billion (2021), compared with a mean of $1.6 billion.
  • Biggest five-year swings in EBT: skyrocketed 955.26% in 2023 and later tumbled 445.08% in 2024.
  • Gilead Sciences' EBT stood at $759.0 million in 2021, then surged by 167.59% to $2.0 billion in 2022, then dropped by 18.61% to $1.7 billion in 2023, then surged by 31.09% to $2.2 billion in 2024, then fell by 4.11% to $2.1 billion in 2025.
  • The last three reported values for EBT were $2.1 billion (Q4 2025), $3.6 billion (Q3 2025), and $2.4 billion (Q2 2025) per Business Quant data.